Special Edition #AIEye Featuring (OTC PINK: $GTCH): #Healthcare
and #Medical - Prominent Segment in Rapidly Growing and Broadening #AI Market
Stocks discussed: (OTC PINK: $GTCH) (NasdaqGS: $MSFT)
(NYSE: $BKR) (NasdaqGS: $NVDA) (NYSE: $PFE) (NYSE: $IBM) (NasdaqGS: $NUAN)
Point Roberts WA, Vancouver BC – January 23,
2020 – Investorideas.com (www.investorideas.com), a global investor news source
covering Artificial Intelligence (AI)
releases a special edition of The AI Eye,
featuring GBT Technologies Inc., (OTC PINK:GTCH).
Read this article
featuring GTCH in full at https://www.investorideas.com/news/2020/artificial-intelligence/01231AIEye-Healthcare-Meidcal.asp
No longer relegated to the ranks of science
fiction, AI is rapidly becoming ubiquitous as one the most dynamic new fields
in technology. But just as it cannot be consigned to fiction, AI cannot be
reducible to any particular tech category, as it demonstrates applicability in
an increasing array of different industries. Its core technologies – such as
machine learning, deep learning, natural language processing (NLP) and computer
vision – have enabled AI to penetrate and become indispensable in everything
from autonomous vehicles, virtual assistants, energy, voice and text
translation, retail, healthcare and more. And this is all happening fast. A
report from Grand View Research,
for instance, projects a compound annual growth rate (CAGR) for the global AI
market of 46.2 percent from 2019 to 2025.
AI development is not merely left to small
private companies and startups, but is well represented by some of the biggest
publicly traded firms on the planet. For example, Microsoft (NasdaqGS:MSFT), along with C3.ai and Baker
Hughes (NYSE:BKR), formed an alliance
late last year to “bring enterprise artificial intelligence (AI) solutions to
the energy industry” using distinct solutions from all three companies running
on the former’s cloud computing service Azure. The adoption of AI by energy
companies streamlines the industry’s “inventory optimization and energy
management to predictive maintenance and process and equipment reliability,''
according to the press release.
Elsewhere, Nvidia Corporation (NasdaqGS:NVDA)
– known primarily for GPUs and SoCs – has recently improved its end-to-end
platform for autonomous vehicle (AV) development by making available
its DRIVE deep neural networks
(DNNs) to the transportation industry. These DNNs facilitate “traffic-light and
sign detection, object detection (for vehicles, pedestrians, bicycles) and path
perception, as well as gaze detection and gesture recognition inside the
vehicle,” making autonomous driving a viable future for transportation.
A particular market that one can observe AI
making considerable advances in, is that of healthcare and medicine. A press release
for the aforementioned report outlines some of the promise that AI is showing
in healthcare with the following excerpt:
AI
has the potential to reduce the burden on clinicians and provide an efficient
tool to workforces for accomplishing their tasks in a better way. For instance,
AI voice-enabled symptom checkers can better access a situation and assist
patients to the emergency department when immediate treatment is required.
Artificial intelligence is expected to resolve around 20% of unmet healthcare
demands.
As AI is relatively new and very dynamic,
it is perhaps unsurprising that a wide variety of approaches and applications
have found their way into the healthcare and medical markets. One approach is
that of development-stage company GBT Technologies Inc. (OTC PINK:GTCH),
a native IoT creator, developer of Internet of Things (IoT) and AI-enabled
mobile technology platforms. Recently, the company announced the implementation
of Recurrent Relational Reasoning (RRN) – “an artificial neural network
component with a structure that can reason about relations among objects” –
into its Avant! intelligent agent. Dr. Danny Rittman, GBT's Chief Technology
Officer explained the effect of this development and how it can be leveraged in
the medical field:
"Our
goal is to implement a fundamental part of human intelligence called relational
reasoning, which is planned to enable Avant! to acquire expertise on its own by
understanding object's relations. Avant! will include an advanced artificial
neural network (ANN) capable of pattern recognition and reasoning about those
patterns which is very similar to the human brain. Rather than operating on
pre-set rules, the system will learn image's patterns by tweaking the relations
between objects, analyzing connections, and building hypotheses about how they
relate to each other. This capability will be used for Avant! imaging system
for upcoming implementation in the medical field. We are creating an
interactive and intuitive intelligent system that performs complex computation
over discrete entities and the relations between them. Our goal is to provide Avant!
a broad range of advantages and capabilities when it comes to intelligent
imaging, especially in the medical domain.”
In an interview with
Investorideas.com, Rittman indicated the applicability of the AI with this RRN
integration:
"If
you want to identify suspicious objects - let's say within an MRI scan or a CT
scan image or an X-ray image - our RRN will actually scan the data, make sure
it actually knows and understands relations between objects ... and then will
be able to alert us.”
"It
is a process of evolution. It will only get better with time."
Elsewhere, multinational pharmaceutical
giant Pfizer, Inc. (NYSE:PFE) recently entered
into a research collaboration
with Insilico Medicine, a company that leverages AI for drug discovery,
biomarker development and aging research. Through the collaboration, Pfizer
will leverage Insilico's machine learning technology and proprietary Pandomics
Discovery Platform to identify “potential therapeutic targets implicated in a
variety of diseases.” Morten Sogaard, Vice President, Target Sciences, Pfizer
commented on the collaboration and the potential yield of utilizing Insilico’s
technology:
"We
look forward to working with Insilico as Pfizer continues to explore new
technologies that may be able to help us identify targets and biomarkers that
could assist in our discovery programs, and potentially lead to breakthrough
therapeutics for patients with unmet medical needs.”
The integration of AI into the drug
discovery field of healthcare however has not been seamless. Pfizer had
previously worked with IBM (NYSE:IBM), who early last
year had to halt “development and sales of a product that uses its Watson
artificial intelligence software to help pharmaceutical companies discover new
drugs” as a result of poor financial performance, according to STAT. However, Watson has
remained a vital force in wider AI in healthcare market, according to news from
the end of last year. A piece from P&T Community reported that at the 105th
RSNA Scientific Assembly and Annual Meeting on December 1, IBM Watson Health
showcased new clients and relationships for its Imaging AI platform. Anne Le
Grand, General Manager, Imaging, Life Sciences and Oncology, IBM Watson Health,
explained:
"We
are delighted to announce these collaborations at RSNA highlighting our
advancements in medical imaging globally. From helping clinicians to identify
potential missed findings to seeing a summary view of patient records quickly,
our innovative technologies are at the forefront of Watson Health's mission to
help enable clinicians to more effectively respond to the world's most pressing
health challenges."
Another way AI has proved advantageous in
health and medicine fields is in the use of medical assistants or advisors. A
key example of this is the Dragon Medical Advisor from Nuance Communications,
Inc. (NasdaqGS:NUAN). Nuance announced an expansion to
the Dragon’s clinical guidance capabilities last autumn, boasting that the
platform “supports diagnoses with relevant clinical information; minimizes
rework from retrospective queries; measures and advances care quality and
financial performance; and supports the appropriate reimbursements for care.”
Michael Clark, Senior Vice President and General Manager, Provider Solutions,
Nuance, explained:
“Dragon
Medical Advisor leverages a comprehensive and continuously expanding knowledge
base in real-time to capture comorbidities, major complications, and other
relevant data in the patient record. The result is higher physician
productivity and satisfaction, improved care quality, and outcomes with more
appropriate reimbursement. Hospitals using this capability have reported
multiple benefits, including significantly fewer retrospective queries from
Clinical Documentation Specialists and Coders.”
An article from TNW argues that AI adoption
in the medical industry is actually saving doctors time, which can mean the
difference between life and death for patients. This can be done through early
diagnosis, enabled by tech such as the AI-powered mobile app Your.MD. According
to the article,Your.MD:
…uses
natural language processing and generation to provide a rich and fluid
experience, and machine learning algorithms to create a complex map of the
user’s condition and provide a personalized experience.
Your.MD
suggests steps and measures to remedy the illness, including warning users when
they need to see a doctor.
Though AI adoption in healthcare and
medical applications are vast and increasing, the technology is penetrating a
wide array of other industries simultaneously. GBT Technologies alone, for
instance, is targeting multiple applications for its Avant! AI, including autonomous machines and robots,
as well as sports handicapping
and more. So, with AI continuing to be one of the most vital and fertile
technology fields in the so-called Fourth Industrial Revolution, one can expect
to see more applications and use cases emerge as the technology develops and
the already impressive benefits continue to accrue.
Sam Mowers, Investorideas.com
For
a list of artificial intelligence stocks on Investorideas.com visit here or become an Investor Ideas member
About Investorideas.com -
News that Inspires Big Investing Ideas Investorideas.com
is a recognized news source publishing third party news and press releases plus
we create original financial content. Learn about investing in stocks and sector trends
from Investorideas.com with our news alerts , articles , podcasts and videos talking about cannabis, crypto,
technology including AI and IoT ,
mining ,sports biotech, water, renewable energy and more . Investorideas.com
original branded content includes the daily Crypto
Corner and Podcast, Play by Play sports and stock
news column, Investor
Ideas #Potcasts #Cannabis News and
Stocks on the Move podcast and column,
Cleantech and Climate Change Podcast and
the AI Eye Podcast and
column covering developments in AI.
The
Investorideas.com podcasts are also available on iTunes, Spotify, Tunein, Stitcher, Spreaker.com,
iHeartRadio and Google Play Music.
Visit
the Podcast page at Investorideas.com:
Disclaimer/Disclosure: Investorideas.com is a
digital publisher of third party sourced news, articles and equity research as
well as creates original content, including video, interviews and articles.
Original content created by investorideas is protected by copyright laws other
than syndication rights. Our site does not make recommendations for purchases
or sale of stocks, services or products. Nothing on our sites should be
construed as an offer or solicitation to buy or sell products or securities.
All investing involves risk and possible losses. This site is currently
compensated for news publication and distribution, social media and marketing,
content creation and more. Disclosure is posted for each compensated news
release, content published /created if required but otherwise the news was not
compensated for and was published for the sole interest of our readers and followers.
Contact management and IR of each company directly regarding specific
questions. Disclosure
GTCH is a paid news and social media client on Investorideas.com More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our
other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com Global investors must adhere to
regulations of each country. Please read Investorideas.com privacy
policy: https://www.investorideas.com/About/Private_Policy.asp
The
AI Eye- Watching stock news, deal tracker and
advancements in artificial intelligence is an original content brand of
Investorideas.com
Contact
Investorideas.com
800 665 0411
